Overview

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This randomized controlled clinical trial will compare the eradication efficacy of bismuth quadruple therapy containing clarithromycin+metronidazole, clarithromycin+levofloxacin, or metronidazole+levofloxacin for Helicobacter pylori first-line treatment in penicillin-allergic patients. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai Zhongshan Hospital
Treatments:
Bismuth
Clarithromycin
Levofloxacin
Metronidazole
Ofloxacin
Potassium Citrate
Rabeprazole